Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Cholangiocarcinoma: An-eight-year Experience in a Tertiary-Center in Iran

  • Mohammad-Alizadeh, Amir Houshang (Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Talegani Hospital) ;
  • Ghobakhlou, Mehdi (Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Talegani Hospital) ;
  • Shalmani, Hamid Mohaghegh (Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Talegani Hospital) ;
  • Zali, Mohammad Reza (Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Talegani Hospital)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Aim: Cholangiocarcinoma (CCA) is an uncommon malignancy of the bile duct, occurring in nearly 2 out of 100,000 people. It is a type of adenocarcinoma that originates in the mucous glands of the epithelium, or surface layers of the bile ducts. The aim of this study was to evaluate the clinical features, diagnostic results and factors associated with survival, morbidity and mortalityof cholangiocarcinoma cases in Iranian patients. Method: In this retrospective study the hospital medical records of 283 patients with a primary or final diagnosis of cholangiocarcinoma who had been admitted to gastroenterology ward of our hospital from 2004 to 2011 were retrospectively reviewed. Results: 283 patients (180 male, 63%, and 103 female, 38.6%) with a mean age of $59.7{\pm}14.4$ years were studied. The most frequent symptoms were painless jaundice (190, 66.9%), abdominal pain (77, 27%), pruritus 133 (46.8%) and weight loss (169, 59.5%). The most frequent associated risk factors and diseases were as follows: gallstones (72, 25.4%), diabetes (70, 24.6%), HBV infection (52 (18.3%), HCV infection 43 (15%), primary sclerosing cholangitis (16, 5.6%) and smoking (120, 42.3%). The most frequent type of cholangiocarcinoma in ERCP and MRCP was hilar. The mean survival time was $7.42{\pm}5.76$ months. Conclusion: The mean survival time in our study was lower than one year. Moreover the most frequent risk factors and associated diseases were smoking, gallstones and diabetes. Painless jaundice, abdominal pain and weight loss were the most clinical features related to cholangiocarcinoma. Additionally survival time did not correlate with risk factors, associated diseases and clinical presentations, but was linked to biliary metallic stenting and surgery.

Keywords

References

  1. Ahrendt SA, Pitt HA (2001). Biliary tract. In: Townsend C, Eds. Sabiston Textbook of Surgery. Philadelphia, W.B. Saunders Company pp 1076-1111.
  2. Alvaro D, Mancino MG (2008). New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med, 29, 50-7. https://doi.org/10.1016/j.mam.2007.09.007
  3. Blechacz B, Gores GJ (2008). Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 48, 308-21.
  4. Burke EC, Jarnagin WR, Hochwald SN, et al (1998). Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg, 228, 385-94. https://doi.org/10.1097/00000658-199809000-00011
  5. Burak K, Angulo P, Pasha TM, et al (2004). Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol, 99, 523-6. https://doi.org/10.1111/j.1572-0241.2004.04067.x
  6. Boberg KM, Bergquist A, Mitchell S, et al (2002). Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol, 37, 1205-11. https://doi.org/10.1080/003655202760373434
  7. Carriaga MT, Henson DE (1995). Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer, 75, 171-90. https://doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2
  8. Cho SY, Park SJ, Kim SH, et al (2010). Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol, 17, 1823-30. https://doi.org/10.1245/s10434-010-0938-y
  9. Khan SA, Davidson BR, Goldin R, et al (2002). Guidelines for the diagnosis and management of cholangiocarcinoma. Gut, 51, 1-I9. https://doi.org/10.1136/gut.51.1.e1
  10. Jan YY, Jeng LB, Hwang TL, et al (1996). Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastroenterology, 43, 614-19.
  11. Park J, Kim MH, Kim KP, et al (2009). Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver, 3, 298-305. https://doi.org/10.5009/gnl.2009.3.4.298
  12. Nagorney DM, Donohue JH, Farnell MB, et al (1993). Outcomes after curative resections of cholangiocarcinoma. Arch Surg, 128, 871-7. https://doi.org/10.1001/archsurg.1993.01420200045008
  13. Nakeeb A, Pitt HA, Sohn TA, et al (1996). Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg, 224, 463-73. https://doi.org/10.1097/00000658-199610000-00005
  14. Shaib YH, El-Serag HB, Davila JA, et al (2002). Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology, 128, 620-6.
  15. Shaib YH, El-Serag HB, Davila JA, et al (2005). Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology, 128, 620-6 https://doi.org/10.1053/j.gastro.2004.12.048
  16. Shaib Y, El-Serag HB (2004). The epidemiology of cholangiocarcinoma. Semin Liver Dis, 24, 115-25. https://doi.org/10.1055/s-2004-828889
  17. Suh KS, Roh HR, Koh YT, et al (2000). Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology, 31, 12-17. https://doi.org/10.1002/hep.510310104
  18. Vauthey JN, Blumgart LH (1994). Recent advances in the management of cholangiocarcinomas. Semin Liver Dis, 14, 109-14. https://doi.org/10.1055/s-2007-1007302
  19. Welzel TM, Graubard BI, El-Serag HB, et al (2007). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol, 5, 1221-8. https://doi.org/10.1016/j.cgh.2007.05.020
  20. Yachimski P, Pratt DS (2008). Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol, 42, 178-90. https://doi.org/10.1097/MCG.0b013e31806daf89

Cited by

  1. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3451
  2. Association between Diabetes Mellitus and Fatty Liver Based on Ultrasonography Screening in the World's Highest Cholangiocarcinoma Incidence Region, Northeast Thailand vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3931